Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR.
Shalabi H, Qin H, Su A, Yates B, Wolters PL, Steinberg SM, Ligon JA, Silbert S, DéDé K, Benzaoui M, Goldberg S, Achar S, Schneider D, Shahani SA, Little L, Foley T, Molina JC, Panch S, Mackall CL, Lee DW, Chien CD, Pouzolles M, Ahlman M, Yuan CM, Wang HW, Wang Y, Inglefield J, Toledo-Tamula MA, Martin S, Highfill SL, Altan-Bonnet G, Stroncek D, Fry TJ, Taylor N, Shah NN. Shalabi H, et al. Among authors: shahani sa. Blood. 2022 Aug 4;140(5):451-463. doi: 10.1182/blood.2022015795. Blood. 2022. PMID: 35605184 Free PMC article. Clinical Trial.
Diagnostic approach to the evaluation of myeloid malignancies following CAR T-cell therapy in B-cell acute lymphoblastic leukemia.
Mo G, Wang HW, Talleur AC, Shahani SA, Yates B, Shalabi H, Douvas MG, Calvo KR, Shern JF, Chaganti S, Patrick K, Song Y, Fry TJ, Wu X, Triplett BM, Khan J, Gardner RA, Shah NN. Mo G, et al. Among authors: shahani sa. J Immunother Cancer. 2020 Nov;8(2):e001563. doi: 10.1136/jitc-2020-001563. J Immunother Cancer. 2020. PMID: 33246985 Free PMC article.
Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomes.
Aldoss I, Pillai R, Yang D, Yang L, Arslan S, Mokhtari S, Malki MMA, Salhotra A, Shahani S, Ali H, Mei M, Artz A, Snyder D, Afkhami M, Armenian S, Stein A, Marcucci G, Forman SJ, Nakamura R, Pullarkat V. Aldoss I, et al. Blood Cancer J. 2021 Jul 2;11(7):125. doi: 10.1038/s41408-021-00516-1. Blood Cancer J. 2021. PMID: 34215723 Free PMC article. No abstract available.
Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days.
Mikkilineni L, Yates B, Steinberg SM, Shahani SA, Molina JC, Palmore T, Lee DW, Kaplan RN, Mackall CL, Fry TJ, Gea-Banacloche J, Jerussi T, Nussenblatt V, Kochenderfer JN, Shah NN. Mikkilineni L, et al. Among authors: shahani sa. Blood Adv. 2021 Dec 14;5(23):5312-5322. doi: 10.1182/bloodadvances.2021004896. Blood Adv. 2021. PMID: 34619768 Free PMC article. Review.
CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity.
Jess J, Yates B, Dulau-Florea A, Parker K, Inglefield J, Lichtenstein D, Schischlik F, Ongkeko M, Wang Y, Shahani S, Cullinane A, Smith H, Kane E, Little L, Chen D, Fry TJ, Shalabi H, Wang HW, Satpathy A, Lozier J, Shah NN. Jess J, et al. J Immunother Cancer. 2023 Jun;11(6):e005898. doi: 10.1136/jitc-2022-005898. J Immunother Cancer. 2023. PMID: 37295816 Free PMC article.
High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia-like fusions.
Aldoss I, Afkhami M, Yang D, Gu Z, Mokhtari S, Shahani S, Pourhassan H, Agrawal V, Koller P, Arslan S, Tomasian V, Al Malki MM, Artz A, Salhotra A, Ali H, Aribi A, Sandhu KS, Ball B, Otoukesh S, Amanam I, Becker PS, Stewart FM, Curtin P, Smith E, Telatar M, Stein AS, Marcucci G, Forman SJ, Nakamura R, Pullarkat V. Aldoss I, et al. Am J Hematol. 2023 Jun;98(6):848-856. doi: 10.1002/ajh.26908. Epub 2023 Mar 16. Am J Hematol. 2023. PMID: 36880203
Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma.
Simonds EF, Lu ED, Badillo O, Karimi S, Liu EV, Tamaki W, Rancan C, Downey KM, Stultz J, Sinha M, McHenry LK, Nasholm NM, Chuntova P, Sundström A, Genoud V, Shahani SA, Wang LD, Brown CE, Walker PR, Swartling FJ, Fong L, Okada H, Weiss WA, Hellström M. Simonds EF, et al. Among authors: shahani sa. J Immunother Cancer. 2021 Jun;9(6):e002181. doi: 10.1136/jitc-2020-002181. J Immunother Cancer. 2021. PMID: 34083417 Free PMC article.
Combined immune checkpoint blockade increases CD8+CD28+PD-1+ effector T cells and provides a therapeutic strategy for patients with neuroblastoma.
Shirinbak S, Chan RY, Shahani S, Muthugounder S, Kennedy R, Hung LT, Fernandez GE, Hadjidaniel MD, Moghimi B, Sheard MA, Epstein AL, Fabbri M, Shimada H, Asgharzadeh S. Shirinbak S, et al. Oncoimmunology. 2021 Jan 4;10(1):1838140. doi: 10.1080/2162402X.2020.1838140. Oncoimmunology. 2021. PMID: 33489468 Free PMC article.
13 results